涩里番

涩里番, in conjunction with Universities Allied for Essential Medicines (UAEM), has committed to increasing access to life-saving medicines by adopting Global Access Licensing Principles. 涩里番 is the third Canadian university to adopt the principles, demonstrating a dedication to ensure that any research and university-developed technologies created on 涩里番鈥檚 campus with potential for further development into a drug, vaccine, or medical diagnostic are made affordable to all.

Global Access Licensing Framework (GALF), the framework used to inform aspects of 涩里番鈥檚 new principles, provides goals and strategies for research universities to follow in the licensing of medicines developed at the universities. The framework aims to prevent patenting practices and intellectual property policies from creating barriers to the life-saving results of publicly-funded research conducted in universities鈥� laboratories. GALF was created with the help of Universities Allied for Essential Medicines (UAEM), a non-profit, student advocacy organization with chapters at universities around the world

The 涩里番 chapter of UAEM has worked alongside Innovation and Partnerships to create a GALF commitment best suited for 涩里番. Students from the 涩里番 UAEM chapter have simultaneously worked to raise awareness of the importance of transparency and equitable licensing of medicines by passing a motion in 涩里番鈥檚 Student Society, meeting with members of the administration, and organizing various creative advocacy events around campus.

The finalized version of 涩里番鈥檚 Global Access Licensing Principles affirms 涩里番鈥檚 commitments to research transparency and to publishing results, commitments shared by the Montreal Neurological Institute鈥檚 Open Science Initiative. It is therefore 涩里番鈥檚 position that the research and development done on campus should serve the public interest by increasing research capacity, enhancing knowledge transfer, or by contributing to the development of useful products, services, and processes. Conditional licensing agreements like GALF are a step towards ensuring a public return on public investment in the production of life-saving medicines.

Included in 涩里番鈥檚 GALF is a commitment to annually report on its licensing activity. By issuing such a report, 涩里番 will acknowledge the impact it can assert through patenting and licensing, an impact supported by the introduction of Global Access Licensing Principles.

Canadian universities have played an historic role in the development of life-saving drugs, for example the discovery of insulin treatment for diabetes at the University of Toronto in 1921. In 1923, insulin鈥檚 patent rights were sold for $1 by Frederick Banting who famously said, 鈥淚nsulin belongs to the world, not me.鈥� As we approach the 100^th anniversary of this discovery and look to the future, 涩里番 and UAEM believe in the value of adopting Global Access Licensing Principles to ensure that no person dies from treatable diseases and that the life-saving fruits of biomedical research are affordable and accessible to patients across Canada and the world.

Read the full GALF commitment on 涩里番 Innovation + Partnerships鈥� new Global Access Principles webpage.

听

Media contact:

Meaghan Thurston, Senior Communications Officer

Research and Innovation
涩里番

tel: (514) 398-3400
meaghan.thurston [at] mcgill.ca

听

听